Performance of Two Interferon-Gamma Release Assays (T-SPOT.TB and QuantiFERON-TB Gold in Tube) Increase Diagnostic Yield of Tuberculin Skin Testing for Detection of Latent Tuberculosis in Patients With Inflammatory Bowel Disease

2011 ◽  
Vol 140 (5) ◽  
pp. S-691 ◽  
Author(s):  
Miguel Arias ◽  
Ruth de Francisco ◽  
Sabino Riestra ◽  
Ana Pando ◽  
Juan José Palacios ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Interferon Gamma ◽  
Bowel Disease ◽  
Diagnostic Yield ◽  
Skin Testing ◽  
Latent Tuberculosis ◽  
Tuberculin Skin Testing ◽  
Interferon Gamma Release Assays ◽  
Inflammatory Bowel

scholarly journals Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study

2018 ◽  
Vol 9 (3) ◽  
pp. 234-240 ◽  
Author(s):  
Aye Aye Thi ◽  
Aula Abbara ◽  
Sonia Bouri ◽  
Simon M Collin ◽  
Paul Wolfson ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Latent Tuberculosis ◽  
Immunosuppressive Drugs ◽  
Retrospective Case ◽  
Biologic Treatment ◽  
North West ◽  
Ltbi Screening ◽  
Interferon Gamma Release Assays ◽  
Inflammatory Bowel

ObjectiveThe aim of this study was to determine the occurrence of latent tuberculosis infections (LTBI) and active TB in a cohort of patients with inflammatory bowel disease (IBD) treated with biologics. We also examined the effects of immunosuppressive drugs on indeterminate interferon-gamma release assays (IGRA) in LTBI screening.DesignRetrospective study of patients treated with biologics between March 2007 and November 2015.SettingSt Mark’s Hospital, North West London, UK.Patients732 patients with IBD who were screened for LTBI using either tuberculin skin test or IGRA before starting a biologic treatment.MethodsRetrospective case note review of all patients with IBD who were screened for LTBI prior to initiating biologics. Patients who developed active TB were identified from the London TB register.ResultsOf 732 patients with IBD, 31 (4.2%) were diagnosed with and treated for LTBI with no significant side effects. Six of 596 patients (1.0%) who received biologic treatment developed active TB. There was a higher proportion of indeterminate IGRA in the immunosuppressive medication group compared with the non-immunosuppressive group (33% (59/181) compared with 9% (6/66), p<0.001). The combination of steroids and thiopurines had the highest proportion of indeterminate IGRA (64%, 16/25). High and low doses of steroids were equally likely to result in an indeterminate IGRA result (67% (8/12) and 57% (4/7), respectively).ConclusionsThis study highlights the challenges of LTBI screening prior to commencing biologic therapy and demonstrates the risk of TB in patients who have been screened and who are receiving prolonged and continuing doses of antitumour necrosis factor.

scholarly journals Tuberculin skin testing in inflammatory bowel disease patients from an endemic area of Brazil

2014 ◽  
Vol 18 (1) ◽  
pp. 60-64 ◽  
Author(s):  
Ingrid Puig Cardoso ◽  
Neogelia Pereira de Almeida ◽  
Daniela Rosa Gotardo ◽  
Mauricio Cardeal ◽  
Genoile Oliveira Santana
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Endemic Area ◽  
Skin Testing ◽  
Tuberculin Skin Testing ◽  
Inflammatory Bowel

scholarly journals Comparison of Interferon-Gamma Release Assay and Tuberculin Skin Test for the Screening of Latent Tuberculosis in Inflammatory Bowel Disease Patients: Indian Scenario

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Alok Kumar Mantri ◽  
Priti Meena ◽  
Amarender Singh Puri ◽  
Ajay Kumar ◽  
Sanjeev Sachdeva ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tuberculin Skin Test ◽  
Skin Test ◽  
Interferon Gamma ◽  
Bowel Disease ◽  
Latent Tuberculosis ◽  
Interferon Gamma Release Assay ◽  
Control Subjects ◽  
Release Assay ◽  
Inflammatory Bowel

Background. In a country like India, where the prevalence of tuberculosis is very high, the role of screening tools for detection of latent tuberculosis infection (LTBI) like TST and IGRA is still unclear, especially in inflammatory bowel disease (IBD) patients. Our study is aimed at comparing the interferon-gamma release assay (IGRA) and tuberculin skin test (TST) to determine the prevalence of LTBI in IBD patients in the Indian subset of the population. Methods. It was a prospective observational analysis. A total of 257 participants were included in the study. Both TST and IGRA were performed in consecutive patients diagnosed with IBD (131 patients) and in 126 healthy individuals. Both tests were performed on the same day. LTBI diagnosis was considered if any one of TST or IGRA was found to be positive. Results. Out of 131 IBD patients, 121 patients had ulcerative colitis and 10 patients had Crohn’s disease. 29% of the IBD patients and 22% of the control subjects had LTBI. The study demonstrated concordance between TST and IGRA. Agreement test kappa value for IBD patients was 0.656 (CI 0.50-0.81), with a p value of <0.001, suggestive of a fair agreement. Mean IFN-γ release was lower in the immunosuppressed group as compared to non-immunosuppressed individuals ( 0.26 ± 0.17 vs. 0.45 ± 0.07 , p = 0.02 ). Cohen’s kappa coefficient values in IBD cases and control subjects were 0.66 and 0.79, respectively. TST was found to be negatively correlated to BMI. Conclusion. Agreement between TST and IGRA was fair in IBD patients. For LTBI screening in IBD patients, TST and IGRA are complementary methods.

Sign in / Sign up

Export Citation Format

Share Document